Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal G Simon

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Frontiers in Systems Neuroscience|December 31, 2013
A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI studyRoyce J Lee, Emil F Coccaro, Henk Cremers, et al.
Journal of Personalized Medicine|October 27, 2022
The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington's DiseaseHilda T Maibach, Michael J Brownstein, Steven M Hersch, et al.
BMC Neuroscience|November 19, 2008
Imaging the neural circuitry and chemical control of aggressive motivationCraig F Ferris, Tara Stolberg, Praveen Kulkarni, et al.
Neuroscience Letters|October 23, 2019
Treating head injury using a novel vasopressin 1a receptor antagonistThomas R Morrison, Praveen Kulkarni, Xuezhu Cai, et al.
Pharmacology, Biochemistry, and Behavior|March 1, 2006
Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behaviorCraig F Ferris, Shi-Fang Lu, Tara Messenger, et al.
Journal of Pharmaceutical Sciences|March 9, 2013
Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonistKarine M Fabio, Christophe D Guillon, Shi-Fang Lu, et al.
Bioorganic & Medicinal Chemistry|January 18, 2012
Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imagingKarine Fabio, Christophe Guillon, Carl J Lacey, et al.
Recent Patents on CNS Drug Discovery|June 10, 2008
Vasopressin antagonists as anxiolytics and antidepressants: recent developmentsNeal G Simon, Christophe Guillon, Karine Fabio, et al.
Contemporary Clinical Trials Communications|April 3, 2023
A proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist for PTSD: Design, methods, and recruitmentJoAnn Difede, Andrew A McAleavey, Mariel Emrich, et al.
Bioorganic & Medicinal Chemistry|January 20, 2007
Azetidinones as vasopressin V1a antagonistsChristophe D Guillon, Gary A Koppel, Michael J Brownstein, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Frontiers in Systems Neuroscience|December 31, 2013
A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI studyRoyce J Lee, Emil F Coccaro, Henk Cremers, et al.
Journal of Personalized Medicine|October 27, 2022
The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington's DiseaseHilda T Maibach, Michael J Brownstein, Steven M Hersch, et al.
BMC Neuroscience|November 19, 2008
Imaging the neural circuitry and chemical control of aggressive motivationCraig F Ferris, Tara Stolberg, Praveen Kulkarni, et al.
Neuroscience Letters|October 23, 2019
Treating head injury using a novel vasopressin 1a receptor antagonistThomas R Morrison, Praveen Kulkarni, Xuezhu Cai, et al.
Pharmacology, Biochemistry, and Behavior|March 1, 2006
Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behaviorCraig F Ferris, Shi-Fang Lu, Tara Messenger, et al.
Journal of Pharmaceutical Sciences|March 9, 2013
Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonistKarine M Fabio, Christophe D Guillon, Shi-Fang Lu, et al.
Bioorganic & Medicinal Chemistry|January 18, 2012
Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imagingKarine Fabio, Christophe Guillon, Carl J Lacey, et al.
Recent Patents on CNS Drug Discovery|June 10, 2008
Vasopressin antagonists as anxiolytics and antidepressants: recent developmentsNeal G Simon, Christophe Guillon, Karine Fabio, et al.
Contemporary Clinical Trials Communications|April 3, 2023
A proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist for PTSD: Design, methods, and recruitmentJoAnn Difede, Andrew A McAleavey, Mariel Emrich, et al.
Bioorganic & Medicinal Chemistry|January 20, 2007
Azetidinones as vasopressin V1a antagonistsChristophe D Guillon, Gary A Koppel, Michael J Brownstein, et al.
Pageof 3